Journal
BLOOD
Volume 123, Issue 10, Pages 1455-1460Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-09-453092
Keywords
-
Categories
Funding
- National Institutes of Health, National Cancer Institute [P01 CA95426, P50CA140158, R01 CA177292]
- Four Winds Foundation
- The Leukemia and Lymphoma Society
- Harry Mangurian Foundation
- Mr. and Mrs. Michael Thomas
- The D. Warren Brown Foundation
Ask authors/readers for more resources
For many years there has been considerable disassociation between the understood biology of chronic lymphocytic leukemia (CLL) and the therapeutics used to treat this disease. With the introduction of the first targeted CD20 antibody rituximab and its addition to chemotherapy came the first observation that minimal residual disease-negative (MRD-negative) complete responses (CRs) could be obtained with dramatically improved progression-free survival and overall survival. This advance was soon to be surpassed by the introduction of therapeutics that target B-cell receptor (BCR) signaling. New data show that BCR-inhibiting agents are very active for the treatment of relapsed CLL, despite the lack of MRD-negative CR, with durability of response being considerably more impressive than previously observed with other agents not producing MRD-negative CRs. This perspective provides a view of where these agents may take us in the future as CLL therapy evolves with this exciting new class of drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available